Financial updates
Pharming Group reports financial results for the first nine months of 2017
Pharming Group N.V., the Dutch specialty pharmaceutical company developing innovative products for the safe, effective treatment of rare diseases and unmet medical needs, presents its (unaudited) financial report for the first nine months and the third quarter ended 30 September 2017.
“These are excellent quarterly results and show that we are on the right track with our strategy for RUCONEST® in all markets.”
- Sijmen de Vries - CEO